Solubilni biomarkeri neurodegenerativnih procesa
Ključne reči:
biomarkeri, neurodegeneracija, CST, krv
Sažetak
Sa produženjem životnog veka u mnogim zemljama se očekuje porast prevalencije neurodegenerativnih bolesti. Utvrđivanje pouzdanih biomarkera neurodegenerativnih bolesti je ključno za unapređenje blagovremene i adekvatne kliničke dijagnoze, razvoj terapija koje utiču na tok bolesti i praćenje pacijenata. Složena patologija neurodegenerativnih bolesti prikazuje se u vanćelijskoj tečnosti, omogućujući razvoj solubilnih biomarkera koji će oslikavati neuropatološke promene u cerebrospinalnoj tečnosti i krvi. Cilj ovog preglednog rada je da ukaže na trenutna saznanja i pravce razvoja primene biomarkera neurodegenerativnih bolesti u telesnim tečnostima.
Reference
1. Naghavi M, Ong KL, Aali A, Ababneh HS, Abate YH, Abbafati C, et al. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2100–32.
2. Lamptey RNL, Chaulagain B, Trivedi R, Gothwal A, Layek B, Singh J. A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics. Int J Mol Sci. 2022;23(3):1851.
3. Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27(6):954–63.
4. Hou Y, Dan X, Babbar M, Wei Y, Hasselbalch SG, Croteau DL, et al. Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol. 2019;15(10):565–81.
5. Elobeid A, Libard S, Leino M, Popova SN, Alafuzoff I. Altered proteins in the aging brain. J Neuropathol Exp Neurol. 2016;75(4):316–25.
6. Lutz W, Sanderson W, Scherbov S. The coming acceleration of global population ageing. Nature. 2008;451(7179):716–9.
7. Atkinson AJ, Colburn WA, DeGruttola VG, DeMets DL, Downing GJ, Hoth DF, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89–95.
8. Thies B, Truschke E, Morrison-Bogorad M, Hodes RJ. Consensus report of the Working Group on: molecular and biochemical markers of Alzheimer’s disease. Neurobiol Aging. 1999;20(2):247.
9. Yilmaz R, Hopfner F, van Eimeren T, Berg D. Biomarkers of Parkinson’s disease: 20 years later. J Neural Transm. 2019;126(7):803–13.
10. Agnello L, Gambino CM, Ciaccio AM, Masucci A, Vassallo R, Tamburello M, et al. Molecular Biomarkers of Neurodegenerative Disorders: A Practical Guide to Their Appropriate Use and Interpretation in Clinical Practice. Int J Mol Sci. 2024;25(8).
11. Hampel H, Hu Y, Cummings J, Mattke S, Iwatsubo T, Nakamura A, et al. Blood-based biomarkers for Alzheimer’s disease: Current state and future use in a transformed global healthcare landscape. Neuron. 2023;111(18):2781–99.
12. Leuzy A, Mattsson‐Carlgren N, Palmqvist S, Janelidze S, Dage JL, Hansson O. Blood‐based biomarkers for Alzheimer’s disease. EMBO Mol Med. 2022;14(1).
13. Müller UC, Deller T, Korte M. Not just amyloid: Physiological functions of the amyloid precursor protein family. Nat Rev Neurosci. 2017;18(5):281–98.
14. Haass C, Kaether C, Thinakaran G, Sisodia S. Trafficking and proteolytic processing of APP. Cold Spring Harb Perspect Med. 2012;2(5).
15. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, et al. The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell-surface receptor. Nature. 1987;325(6106):733–6.
16. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science. 2002;297(5580):353–6.
17. Palmqvist S, Mattsson N, Hansson O. Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography. Brain. 2016;139(4):1226–36.
18. Buchhave P, Minthon L, Zetterberg H, Wallin ÅK, Blennow K, Hansson O. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry. 2012;69(1):98–106.
19. Portelius E, Westman-Brinkmalm A, Zetterberg H, Blennow K. Determination of β-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. J Proteome Res. 2006;5(4):1010–6.
20. Hansson O, Lehmann S, Otto M, Zetterberg H, Lewczuk P. Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease. Alzheimer’s Res Ther. 2019;11(1):1–15.
21. Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, et al. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology. 2019;93(17):E1647–59.
22. Lewczuk P, Matzen A, Blennow K, Parnetti L, Molinuevo JL, Eusebi P, et al. Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer’s Disease. J Alzheimer’s Dis. 2017;55(2):813–22.
23. Mehta PD, Pirttilä T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol. 2000;57(1):100–5.
24. Jack CR, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup. Alzheimers Dement. 2024;20(8):5143–69.
25. Verberk IMW, Thijssen E, Koelewijn J, Mauroo K, Vanbrabant J, De Wilde A, et al. Combination of plasma amyloid beta(1-42/1-40)and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. Alzheimer’s Res Ther. 2020 Sep 28;12(1).
26. Janelidze S, Palmqvist S, Leuzy A, Stomrud E, Verberk IMW, Zetterberg H, et al. Detecting amyloid positivity in early Alzheimer’s disease using combinations of plasma Aβ42/Aβ40 and p-tau. Alzheimer’s Dement. 2022;18(2):283–93.
27. Irwin DJ, Fedler J, Coffey CS, Caspell-Garcia C, Kang JH, Simuni T, et al. Evolution of Alzheimer’s Disease Cerebrospinal Fluid Biomarkers in Early Parkinson’s Disease. Ann Neurol. 2020;88(3):574–87.
28. Janelidze S, Stomrud E, Palmqvist S, Zetterberg H, Van Westen D, Jeromin A, et al. Plasma β-amyloid in Alzheimer’s disease and vascular disease. Sci Rep. 2016;6.
29. Lambert JC, Dallongeville J, Ellis KA, Schraen-Maschke S, Lui J, Laws S, et al. Association of plasma Aß peptides with blood pressure in the elderly. PLoS One. 2011;6(4).
30. Shahnawaz M, Mukherjee A, Pritzkow S, Mendez N, Rabadia P, Liu X, et al. Discriminating α-synuclein strains in Parkinson’s disease and multiple system atrophy. Nature. 2020;578(7794):273–7.
31. Koga S, Sekiya H, Kondru N, Ross OA, Dickson DW. Neuropathology and molecular diagnosis of Synucleinopathies. Mol Neurodegener. 2021;16(1).
32. Graves NJ, Gambin Y, Sierecki E. α-Synuclein Strains and Their Relevance to Parkinson’s Disease, Multiple System Atrophy, and Dementia with Lewy Bodies. Int J Mol Sci. 2023;24(15).
33. Parnetti L, Gaetani L, Eusebi P, Paciotti S, Hansson O, El-Agnaf O, et al. CSF and blood biomarkers for Parkinson’s disease. Lancet Neurol. 2019;18(6):573–86.
34. Mollenhauer B, Caspell-Garcia CJ, Coffey CS, Taylor P, Shaw LM, Trojanowski JQ, et al. Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls. Neurology. 2017;89(19):1959–69.
35. Jiménez-Jiménez FJ, Alonso-Navarro H, García-Martín E, Santos-García D, Martínez-Valbuena I, Agúndez JAG. Alpha-Synuclein in Peripheral Tissues as a Possible Marker for Neurological Diseases and Other Medical Conditions. Biomolecules. 2023;13(8).
36. Zubelzu M, Morera-Herreras T, Irastorza G, Gómez-Esteban JC, Murueta-Goyena A. Plasma and serum alpha-synuclein as a biomarker in Parkinson’s disease: A meta-analysis. Park Relat Disord. 2022;99:107–15.
37. Agnello L, Lo Sasso B, Vidali M, Scazzone C, Gambino CM, Piccoli T, et al. Evaluation of Alpha-Synuclein Cerebrospinal Fluid Levels in Several Neurological Disorders. J Clin Med. 2022;11(11).
38. Koehler NKU, Stransky E, Meyer M, Gaertner S, Shing M, Schnaidt M, et al. Alpha-synuclein levels in blood plasma decline with healthy aging. PLoS One. 2015;10(4).
39. Zhang N, Yan Z, Xin H, Shao S, Xue S, Cespuglio R, et al. Relationship among α‑synuclein, aging and inflammation in Parkinson’s disease (Review). Exp Ther Med. 2024;27(1):23.
40. Buchholz S, Zempel H. The six brain-specific TAU isoforms and their role in Alzheimer’s disease and related neurodegenerative dementia syndromes. Alzheimer’s Dement. 2024;20(5):3606–28.
41. Zhang Y, Wu KM, Yang L, Dong Q, Yu JT. Tauopathies: new perspectives and challenges. Mol Neurodegener. 2022;17(1).
42. Teunissen CE, Verberk IMW, Thijssen EH, Vermunt L, Hansson O, Zetterberg H, et al. Blood-based biomarkers for Alzheimer’s disease: towards clinical implementation. Lancet Neurol. 2022;21(1):66–77.
43. Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19(5):422–33.
44. Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, et al. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA - J Am Med Assoc. 2020;324(8):772–81.
45. Palmqvist S, Janelidze S, Stomrud E, Zetterberg H, Karl J, Zink K, et al. Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status. JAMA Neurol. 2019;76(9):1060–9.
46. Suárez-Calvet M. CSF p-tau231: A biomarker for early preclinical Alzheimer? eBioMedicine. 2022;77.
47. Rissman RA, Langford O, Raman R, Donohue MC, Abdel-Latif S, Meyer MR, et al. Plasma Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer’s disease. Alzheimer’s Dement. 2024;20(2):1214–24.
48. Palmqvist S, Tideman P, Mattsson-Carlgren N, Schindler SE, Smith R, Ossenkoppele R, et al. Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care. JAMA. 2024;
49. Janelidze S, Barthélemy NR, Salvadó G, Schindler SE, Palmqvist S, Mattsson-Carlgren N, et al. Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive Impairment. JAMA Neurol. 2024;81(9):947–57.
50. Therriault J, Vermeiren M, Servaes S, Tissot C, Ashton NJ, Benedet AL, et al. Association of Phosphorylated Tau Biomarkers with Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography. JAMA Neurol. 2023;80(2):188–99.
51. Horie K, Salvadó G, Barthélemy NR, Janelidze S, Li Y, He Y, et al. CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease. Nat Med. 2023;29(8):1954–63.
52. Rasmussen MK, Mestre H, Nedergaard M. The glymphatic pathway in neurological disorders. Lancet Neurol. 2018;17(11):1016–24.
53. Mattsson N, Andreasson U, Zetterberg H, Blennow K, Weiner MW, Aisen P, et al. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2017;74(5):557–66.
54. Lu CH, Macdonald-Wallis C, Gray E, Pearce N, Petzold A, Norgren N, et al. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015;84(22):2247–57.
55. Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14(10):577–89.
56. Zetterberg H, Schott JM. Biomarkers for Alzheimer’s disease beyond amyloid and tau. Nat Med. 2019;25(2):201–3.
57. Kaeser SA, Lehallier B, Thinggaard M, Häsler LM, Apel A, Bergmann C, et al. A neuronal blood marker is associated with mortality in old age. Nat Aging. 2021;1(2):218–25.
58. O’Bryant S, Petersen M, Hall J, Johnson L, Yaffe K, Braskie M, et al. Characterizing plasma NfL in a community-dwelling multi-ethnic cohort: Results from the HABLE study. Alzheimer’s Dement. 2022;18(2):240–50.
59. Idland AV, Sala-Llonch R, Borza T, Watne LO, Wyller TB, Brækhus A, et al. CSF neurofilament light levels predict hippocampal atrophy in cognitively healthy older adults. Neurobiol Aging. 2017;49:138–44.
60. Forgrave LM, Ma M, Best JR, DeMarco ML. The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer’s disease, frontotemporal dementia, and amyotrophic lateral sclerosis: A systematic review and meta-analysis. Alzheimer’s Dement Diagnosis, Assess Dis Monit. 2019;11:730–43.
61. Mielke MM, Syrjanen JA, Blennow K, Zetterberg H, Vemuri P, Skoog I, et al. Plasma and CSF neurofilament light: Relation to longitudinal neuroimaging and cognitive measures. Neurology. 2019;93(3):E252–60.
62. He L, Morley JE, Aggarwal G, Nguyen AD, Vellas B, de Souto Barreto P, et al. Plasma neurofilament light chain is associated with cognitive decline in non-dementia older adults. Sci Rep. 2021;11(1).
63. Osborn KE, Khan OA, Kresge HA, Bown CW, Liu D, Moore EE, et al. Cerebrospinal fluid and plasma neurofilament light relate to abnormal cognition. Alzheimer’s Dement Diagnosis, Assess Dis Monit. 2019;11:700–9.
64. Tang R, Buchholz E, Dale AM, Rissman RA, Fennema-Notestine C, Gillespie NA, et al. Associations of plasma neurofilament light chain with cognition and neuroimaging measures in community-dwelling early old age men. Alzheimer’s Res Ther. 2024;16(1).
65. He L, De Souto Barreto P, Aggarwal G, Nguyen AD, Morley JE, Li Y, et al. Plasma Aβ and neurofilament light chain are associated with cognitive and physical function decline in non-dementia older adults. Alzheimer’s Res Ther. 2020;12(1).
66. Bittner S, Oh J, Havrdová EK, Tintoré M, Zipp F. The potential of serum neurofilament as biomarker for multiple sclerosis. Brain. 2021;144(10):2954–63.
67. Messing A, Brenner M. GFAP at 50. ASN Neuro. 2020;12.
68. Alawode DOT, Fox NC, Zetterberg H, Heslegrave AJ. Alzheimer’s Disease Biomarkers Revisited From the Amyloid Cascade Hypothesis Standpoint. Front Neurosci. 2022;16.
69. Benedet AL, Milà-Alomà M, Vrillon A, Ashton NJ, Pascoal TA, Lussier F, et al. Differences between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels across the Alzheimer Disease Continuum. JAMA Neurol. 2021;78(12):1471–83.
70. Mendes AJ, Ribaldi F, Lathuiliere A, Ashton NJ, Zetterberg H, Abramowicz M, et al. Comparison of plasma and neuroimaging biomarkers to predict cognitive decline in non-demented memory clinic patients. Alzheimer’s Res Ther . 2024;16(1).
71. Cicognola C, Janelidze S, Hertze J, Zetterberg H, Blennow K, Mattsson-Carlgren N, et al. Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. Alzheimer’s Res Ther. 2021;13(1).
72. Chatterjee P, Pedrini S, Stoops E, Goozee K, Villemagne VL, Asih PR, et al. Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease. Transl Psychiatry. 2021;11(1).
73. Verberk IMW, Laarhuis MB, van den Bosch KA, Ebenau JL, van Leeuwenstijn M, Prins ND, et al. Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. Lancet Heal Longev. 2021;2(2):e87–95.
74. Wang R, Zhan Y, Zhu W, Yang Q, Pei J. Association of soluble TREM2 with Alzheimer’s disease and mild cognitive impairment: a systematic review and meta-analysis. Front Aging Neurosci. 2024;16.
75. Jericó I, Vicuña-Urriza J, Blanco-Luquin I, Macias M, Martinez-Merino L, Roldán M, et al. Profiling TREM2 expression in amyotrophic lateral sclerosis. Brain Behav Immun. 2023;109:117–26.
76. Zhang X, Zhong X, Wang L, Li H, Yang L, Li X, et al. Effects of soluble TREM2 on motor progression in Parkinson’s disease. Neurosci Lett. 2023;807.
77. Villar-Piqué A, Schmitz M, Hermann P, Goebel S, Bunck T, Varges D, et al. Plasma YKL-40 in the spectrum of neurodegenerative dementia. J Neuroinflammation. 2019;16(1).
78. Blanco-Palmero VA, Rubio-Fernández M, Antequera D, Villarejo-Galende A, Molina JA, Ferrer I, et al. Increased YKL-40 but Not C-Reactive Protein Levels in Patients with Alzheimer’s Disease. Biomedicines. 2021;9(9).
79. Zhang Y, Tian J, Ni J, Wei M, Li T, Shi J. Peripheral Blood and Cerebrospinal Fluid Levels of YKL-40 in Alzheimer’s Disease: A Systematic Review and Meta-Analysis. Brain Sci. 2023;13(10).
80. Thordardottir S, Almkvist O, Johansson C, Zetterberg H, Blennow K, Graff C. Cerebrospinal Fluid YKL-40 and Neurogranin in Familial Alzheimer’s Disease: A Pilot Study. J Alzheimer’s Dis. 2020;76(3):941–53.
81. Gaetani L, Paolini Paoletti F, Bellomo G, Mancini A, Simoni S, Di Filippo M, et al. CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for Treatment. Trends Pharmacol Sci. 2020;41(12):1023–37.
82. Portelius E, Olsson B, Höglund K, Cullen NC, Kvartsberg H, Andreasson U, et al. Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. Acta Neuropathol. 2018;136(3):363–76.
83. Mavroudis IA, Petridis F, Chatzikonstantinou S, Kazis D. A meta-analysis on CSF neurogranin levels for the diagnosis of Alzheimer’s disease and mild cognitive impairment. Aging Clin Exp Res. 2020;32(9):1639–46.
84. Xiang Y, Xin J, Le W, Yang Y. Neurogranin: A Potential Biomarker of Neurological and Mental Diseases. Front Aging Neurosci. 2020;12.
85. De Vos A, Bjerke M, Brouns R, De Roeck N, Jacobs D, Van den Abbeele L, et al. Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke. BMC Neurol. 2017;17(1).
86. Pais M V, Forlenza O V, Diniz BS. Plasma Biomarkers of Alzheimer’s Disease: A Review of Available Assays, Recent Developments, and Implications for Clinical Practice. J Alzheimer’s Dis reports. 2023;7(1):355–80.
87. Rissin DM, Kan CW, Campbell TG, Howes SC, Fournier DR, Song L, et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol. 2010;28(6):595–9.
88. Janelidze S, Bali D, Ashton NJ, Barthelemy NR, Vanbrabant J, Stoops E, et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease. Brain. 2023;146(4):1592–601.
89. Bayoumy S, Verberk IMW, den Dulk B, Hussainali Z, Zwan M, van der Flier WM, et al. Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. Alzheimer’s Res Ther. 2021;13(1).
90. Korecka M, Shaw LM. Mass spectrometry-based methods for robust measurement of Alzheimer’s disease biomarkers in biological fluids. J Neurochem. 2021;159(2):211–33.
91. Barthélemy NR, Horie K, Sato C, Bateman RJ. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease. J Exp Med. 2020;217(11).
92. Grossauer A, Hemicker G, Krismer F, Peball M, Djamshidian A, Poewe W, et al. α-Synuclein Seed Amplification Assays in the Diagnosis of Synucleinopathies Using Cerebrospinal Fluid-A Systematic Review and Meta-Analysis. Mov Disord Clin Pract. 2023;10(5):737–47.
93. Morris HR, Lees AJ. Limitations of the α-Synuclein Seed Amplification Assay in Clinical Practice: Understanding the Pathological Diversity of Parkinson Syndrome. JAMA Neurol. 2024;81(9):905–6.
2. Lamptey RNL, Chaulagain B, Trivedi R, Gothwal A, Layek B, Singh J. A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics. Int J Mol Sci. 2022;23(3):1851.
3. Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27(6):954–63.
4. Hou Y, Dan X, Babbar M, Wei Y, Hasselbalch SG, Croteau DL, et al. Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol. 2019;15(10):565–81.
5. Elobeid A, Libard S, Leino M, Popova SN, Alafuzoff I. Altered proteins in the aging brain. J Neuropathol Exp Neurol. 2016;75(4):316–25.
6. Lutz W, Sanderson W, Scherbov S. The coming acceleration of global population ageing. Nature. 2008;451(7179):716–9.
7. Atkinson AJ, Colburn WA, DeGruttola VG, DeMets DL, Downing GJ, Hoth DF, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89–95.
8. Thies B, Truschke E, Morrison-Bogorad M, Hodes RJ. Consensus report of the Working Group on: molecular and biochemical markers of Alzheimer’s disease. Neurobiol Aging. 1999;20(2):247.
9. Yilmaz R, Hopfner F, van Eimeren T, Berg D. Biomarkers of Parkinson’s disease: 20 years later. J Neural Transm. 2019;126(7):803–13.
10. Agnello L, Gambino CM, Ciaccio AM, Masucci A, Vassallo R, Tamburello M, et al. Molecular Biomarkers of Neurodegenerative Disorders: A Practical Guide to Their Appropriate Use and Interpretation in Clinical Practice. Int J Mol Sci. 2024;25(8).
11. Hampel H, Hu Y, Cummings J, Mattke S, Iwatsubo T, Nakamura A, et al. Blood-based biomarkers for Alzheimer’s disease: Current state and future use in a transformed global healthcare landscape. Neuron. 2023;111(18):2781–99.
12. Leuzy A, Mattsson‐Carlgren N, Palmqvist S, Janelidze S, Dage JL, Hansson O. Blood‐based biomarkers for Alzheimer’s disease. EMBO Mol Med. 2022;14(1).
13. Müller UC, Deller T, Korte M. Not just amyloid: Physiological functions of the amyloid precursor protein family. Nat Rev Neurosci. 2017;18(5):281–98.
14. Haass C, Kaether C, Thinakaran G, Sisodia S. Trafficking and proteolytic processing of APP. Cold Spring Harb Perspect Med. 2012;2(5).
15. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, et al. The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell-surface receptor. Nature. 1987;325(6106):733–6.
16. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science. 2002;297(5580):353–6.
17. Palmqvist S, Mattsson N, Hansson O. Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography. Brain. 2016;139(4):1226–36.
18. Buchhave P, Minthon L, Zetterberg H, Wallin ÅK, Blennow K, Hansson O. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry. 2012;69(1):98–106.
19. Portelius E, Westman-Brinkmalm A, Zetterberg H, Blennow K. Determination of β-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. J Proteome Res. 2006;5(4):1010–6.
20. Hansson O, Lehmann S, Otto M, Zetterberg H, Lewczuk P. Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease. Alzheimer’s Res Ther. 2019;11(1):1–15.
21. Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, et al. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology. 2019;93(17):E1647–59.
22. Lewczuk P, Matzen A, Blennow K, Parnetti L, Molinuevo JL, Eusebi P, et al. Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer’s Disease. J Alzheimer’s Dis. 2017;55(2):813–22.
23. Mehta PD, Pirttilä T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol. 2000;57(1):100–5.
24. Jack CR, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup. Alzheimers Dement. 2024;20(8):5143–69.
25. Verberk IMW, Thijssen E, Koelewijn J, Mauroo K, Vanbrabant J, De Wilde A, et al. Combination of plasma amyloid beta(1-42/1-40)and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. Alzheimer’s Res Ther. 2020 Sep 28;12(1).
26. Janelidze S, Palmqvist S, Leuzy A, Stomrud E, Verberk IMW, Zetterberg H, et al. Detecting amyloid positivity in early Alzheimer’s disease using combinations of plasma Aβ42/Aβ40 and p-tau. Alzheimer’s Dement. 2022;18(2):283–93.
27. Irwin DJ, Fedler J, Coffey CS, Caspell-Garcia C, Kang JH, Simuni T, et al. Evolution of Alzheimer’s Disease Cerebrospinal Fluid Biomarkers in Early Parkinson’s Disease. Ann Neurol. 2020;88(3):574–87.
28. Janelidze S, Stomrud E, Palmqvist S, Zetterberg H, Van Westen D, Jeromin A, et al. Plasma β-amyloid in Alzheimer’s disease and vascular disease. Sci Rep. 2016;6.
29. Lambert JC, Dallongeville J, Ellis KA, Schraen-Maschke S, Lui J, Laws S, et al. Association of plasma Aß peptides with blood pressure in the elderly. PLoS One. 2011;6(4).
30. Shahnawaz M, Mukherjee A, Pritzkow S, Mendez N, Rabadia P, Liu X, et al. Discriminating α-synuclein strains in Parkinson’s disease and multiple system atrophy. Nature. 2020;578(7794):273–7.
31. Koga S, Sekiya H, Kondru N, Ross OA, Dickson DW. Neuropathology and molecular diagnosis of Synucleinopathies. Mol Neurodegener. 2021;16(1).
32. Graves NJ, Gambin Y, Sierecki E. α-Synuclein Strains and Their Relevance to Parkinson’s Disease, Multiple System Atrophy, and Dementia with Lewy Bodies. Int J Mol Sci. 2023;24(15).
33. Parnetti L, Gaetani L, Eusebi P, Paciotti S, Hansson O, El-Agnaf O, et al. CSF and blood biomarkers for Parkinson’s disease. Lancet Neurol. 2019;18(6):573–86.
34. Mollenhauer B, Caspell-Garcia CJ, Coffey CS, Taylor P, Shaw LM, Trojanowski JQ, et al. Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls. Neurology. 2017;89(19):1959–69.
35. Jiménez-Jiménez FJ, Alonso-Navarro H, García-Martín E, Santos-García D, Martínez-Valbuena I, Agúndez JAG. Alpha-Synuclein in Peripheral Tissues as a Possible Marker for Neurological Diseases and Other Medical Conditions. Biomolecules. 2023;13(8).
36. Zubelzu M, Morera-Herreras T, Irastorza G, Gómez-Esteban JC, Murueta-Goyena A. Plasma and serum alpha-synuclein as a biomarker in Parkinson’s disease: A meta-analysis. Park Relat Disord. 2022;99:107–15.
37. Agnello L, Lo Sasso B, Vidali M, Scazzone C, Gambino CM, Piccoli T, et al. Evaluation of Alpha-Synuclein Cerebrospinal Fluid Levels in Several Neurological Disorders. J Clin Med. 2022;11(11).
38. Koehler NKU, Stransky E, Meyer M, Gaertner S, Shing M, Schnaidt M, et al. Alpha-synuclein levels in blood plasma decline with healthy aging. PLoS One. 2015;10(4).
39. Zhang N, Yan Z, Xin H, Shao S, Xue S, Cespuglio R, et al. Relationship among α‑synuclein, aging and inflammation in Parkinson’s disease (Review). Exp Ther Med. 2024;27(1):23.
40. Buchholz S, Zempel H. The six brain-specific TAU isoforms and their role in Alzheimer’s disease and related neurodegenerative dementia syndromes. Alzheimer’s Dement. 2024;20(5):3606–28.
41. Zhang Y, Wu KM, Yang L, Dong Q, Yu JT. Tauopathies: new perspectives and challenges. Mol Neurodegener. 2022;17(1).
42. Teunissen CE, Verberk IMW, Thijssen EH, Vermunt L, Hansson O, Zetterberg H, et al. Blood-based biomarkers for Alzheimer’s disease: towards clinical implementation. Lancet Neurol. 2022;21(1):66–77.
43. Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19(5):422–33.
44. Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, et al. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA - J Am Med Assoc. 2020;324(8):772–81.
45. Palmqvist S, Janelidze S, Stomrud E, Zetterberg H, Karl J, Zink K, et al. Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status. JAMA Neurol. 2019;76(9):1060–9.
46. Suárez-Calvet M. CSF p-tau231: A biomarker for early preclinical Alzheimer? eBioMedicine. 2022;77.
47. Rissman RA, Langford O, Raman R, Donohue MC, Abdel-Latif S, Meyer MR, et al. Plasma Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer’s disease. Alzheimer’s Dement. 2024;20(2):1214–24.
48. Palmqvist S, Tideman P, Mattsson-Carlgren N, Schindler SE, Smith R, Ossenkoppele R, et al. Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care. JAMA. 2024;
49. Janelidze S, Barthélemy NR, Salvadó G, Schindler SE, Palmqvist S, Mattsson-Carlgren N, et al. Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive Impairment. JAMA Neurol. 2024;81(9):947–57.
50. Therriault J, Vermeiren M, Servaes S, Tissot C, Ashton NJ, Benedet AL, et al. Association of Phosphorylated Tau Biomarkers with Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography. JAMA Neurol. 2023;80(2):188–99.
51. Horie K, Salvadó G, Barthélemy NR, Janelidze S, Li Y, He Y, et al. CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease. Nat Med. 2023;29(8):1954–63.
52. Rasmussen MK, Mestre H, Nedergaard M. The glymphatic pathway in neurological disorders. Lancet Neurol. 2018;17(11):1016–24.
53. Mattsson N, Andreasson U, Zetterberg H, Blennow K, Weiner MW, Aisen P, et al. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2017;74(5):557–66.
54. Lu CH, Macdonald-Wallis C, Gray E, Pearce N, Petzold A, Norgren N, et al. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015;84(22):2247–57.
55. Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14(10):577–89.
56. Zetterberg H, Schott JM. Biomarkers for Alzheimer’s disease beyond amyloid and tau. Nat Med. 2019;25(2):201–3.
57. Kaeser SA, Lehallier B, Thinggaard M, Häsler LM, Apel A, Bergmann C, et al. A neuronal blood marker is associated with mortality in old age. Nat Aging. 2021;1(2):218–25.
58. O’Bryant S, Petersen M, Hall J, Johnson L, Yaffe K, Braskie M, et al. Characterizing plasma NfL in a community-dwelling multi-ethnic cohort: Results from the HABLE study. Alzheimer’s Dement. 2022;18(2):240–50.
59. Idland AV, Sala-Llonch R, Borza T, Watne LO, Wyller TB, Brækhus A, et al. CSF neurofilament light levels predict hippocampal atrophy in cognitively healthy older adults. Neurobiol Aging. 2017;49:138–44.
60. Forgrave LM, Ma M, Best JR, DeMarco ML. The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer’s disease, frontotemporal dementia, and amyotrophic lateral sclerosis: A systematic review and meta-analysis. Alzheimer’s Dement Diagnosis, Assess Dis Monit. 2019;11:730–43.
61. Mielke MM, Syrjanen JA, Blennow K, Zetterberg H, Vemuri P, Skoog I, et al. Plasma and CSF neurofilament light: Relation to longitudinal neuroimaging and cognitive measures. Neurology. 2019;93(3):E252–60.
62. He L, Morley JE, Aggarwal G, Nguyen AD, Vellas B, de Souto Barreto P, et al. Plasma neurofilament light chain is associated with cognitive decline in non-dementia older adults. Sci Rep. 2021;11(1).
63. Osborn KE, Khan OA, Kresge HA, Bown CW, Liu D, Moore EE, et al. Cerebrospinal fluid and plasma neurofilament light relate to abnormal cognition. Alzheimer’s Dement Diagnosis, Assess Dis Monit. 2019;11:700–9.
64. Tang R, Buchholz E, Dale AM, Rissman RA, Fennema-Notestine C, Gillespie NA, et al. Associations of plasma neurofilament light chain with cognition and neuroimaging measures in community-dwelling early old age men. Alzheimer’s Res Ther. 2024;16(1).
65. He L, De Souto Barreto P, Aggarwal G, Nguyen AD, Morley JE, Li Y, et al. Plasma Aβ and neurofilament light chain are associated with cognitive and physical function decline in non-dementia older adults. Alzheimer’s Res Ther. 2020;12(1).
66. Bittner S, Oh J, Havrdová EK, Tintoré M, Zipp F. The potential of serum neurofilament as biomarker for multiple sclerosis. Brain. 2021;144(10):2954–63.
67. Messing A, Brenner M. GFAP at 50. ASN Neuro. 2020;12.
68. Alawode DOT, Fox NC, Zetterberg H, Heslegrave AJ. Alzheimer’s Disease Biomarkers Revisited From the Amyloid Cascade Hypothesis Standpoint. Front Neurosci. 2022;16.
69. Benedet AL, Milà-Alomà M, Vrillon A, Ashton NJ, Pascoal TA, Lussier F, et al. Differences between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels across the Alzheimer Disease Continuum. JAMA Neurol. 2021;78(12):1471–83.
70. Mendes AJ, Ribaldi F, Lathuiliere A, Ashton NJ, Zetterberg H, Abramowicz M, et al. Comparison of plasma and neuroimaging biomarkers to predict cognitive decline in non-demented memory clinic patients. Alzheimer’s Res Ther . 2024;16(1).
71. Cicognola C, Janelidze S, Hertze J, Zetterberg H, Blennow K, Mattsson-Carlgren N, et al. Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. Alzheimer’s Res Ther. 2021;13(1).
72. Chatterjee P, Pedrini S, Stoops E, Goozee K, Villemagne VL, Asih PR, et al. Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease. Transl Psychiatry. 2021;11(1).
73. Verberk IMW, Laarhuis MB, van den Bosch KA, Ebenau JL, van Leeuwenstijn M, Prins ND, et al. Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. Lancet Heal Longev. 2021;2(2):e87–95.
74. Wang R, Zhan Y, Zhu W, Yang Q, Pei J. Association of soluble TREM2 with Alzheimer’s disease and mild cognitive impairment: a systematic review and meta-analysis. Front Aging Neurosci. 2024;16.
75. Jericó I, Vicuña-Urriza J, Blanco-Luquin I, Macias M, Martinez-Merino L, Roldán M, et al. Profiling TREM2 expression in amyotrophic lateral sclerosis. Brain Behav Immun. 2023;109:117–26.
76. Zhang X, Zhong X, Wang L, Li H, Yang L, Li X, et al. Effects of soluble TREM2 on motor progression in Parkinson’s disease. Neurosci Lett. 2023;807.
77. Villar-Piqué A, Schmitz M, Hermann P, Goebel S, Bunck T, Varges D, et al. Plasma YKL-40 in the spectrum of neurodegenerative dementia. J Neuroinflammation. 2019;16(1).
78. Blanco-Palmero VA, Rubio-Fernández M, Antequera D, Villarejo-Galende A, Molina JA, Ferrer I, et al. Increased YKL-40 but Not C-Reactive Protein Levels in Patients with Alzheimer’s Disease. Biomedicines. 2021;9(9).
79. Zhang Y, Tian J, Ni J, Wei M, Li T, Shi J. Peripheral Blood and Cerebrospinal Fluid Levels of YKL-40 in Alzheimer’s Disease: A Systematic Review and Meta-Analysis. Brain Sci. 2023;13(10).
80. Thordardottir S, Almkvist O, Johansson C, Zetterberg H, Blennow K, Graff C. Cerebrospinal Fluid YKL-40 and Neurogranin in Familial Alzheimer’s Disease: A Pilot Study. J Alzheimer’s Dis. 2020;76(3):941–53.
81. Gaetani L, Paolini Paoletti F, Bellomo G, Mancini A, Simoni S, Di Filippo M, et al. CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for Treatment. Trends Pharmacol Sci. 2020;41(12):1023–37.
82. Portelius E, Olsson B, Höglund K, Cullen NC, Kvartsberg H, Andreasson U, et al. Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. Acta Neuropathol. 2018;136(3):363–76.
83. Mavroudis IA, Petridis F, Chatzikonstantinou S, Kazis D. A meta-analysis on CSF neurogranin levels for the diagnosis of Alzheimer’s disease and mild cognitive impairment. Aging Clin Exp Res. 2020;32(9):1639–46.
84. Xiang Y, Xin J, Le W, Yang Y. Neurogranin: A Potential Biomarker of Neurological and Mental Diseases. Front Aging Neurosci. 2020;12.
85. De Vos A, Bjerke M, Brouns R, De Roeck N, Jacobs D, Van den Abbeele L, et al. Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke. BMC Neurol. 2017;17(1).
86. Pais M V, Forlenza O V, Diniz BS. Plasma Biomarkers of Alzheimer’s Disease: A Review of Available Assays, Recent Developments, and Implications for Clinical Practice. J Alzheimer’s Dis reports. 2023;7(1):355–80.
87. Rissin DM, Kan CW, Campbell TG, Howes SC, Fournier DR, Song L, et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol. 2010;28(6):595–9.
88. Janelidze S, Bali D, Ashton NJ, Barthelemy NR, Vanbrabant J, Stoops E, et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease. Brain. 2023;146(4):1592–601.
89. Bayoumy S, Verberk IMW, den Dulk B, Hussainali Z, Zwan M, van der Flier WM, et al. Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. Alzheimer’s Res Ther. 2021;13(1).
90. Korecka M, Shaw LM. Mass spectrometry-based methods for robust measurement of Alzheimer’s disease biomarkers in biological fluids. J Neurochem. 2021;159(2):211–33.
91. Barthélemy NR, Horie K, Sato C, Bateman RJ. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease. J Exp Med. 2020;217(11).
92. Grossauer A, Hemicker G, Krismer F, Peball M, Djamshidian A, Poewe W, et al. α-Synuclein Seed Amplification Assays in the Diagnosis of Synucleinopathies Using Cerebrospinal Fluid-A Systematic Review and Meta-Analysis. Mov Disord Clin Pract. 2023;10(5):737–47.
93. Morris HR, Lees AJ. Limitations of the α-Synuclein Seed Amplification Assay in Clinical Practice: Understanding the Pathological Diversity of Parkinson Syndrome. JAMA Neurol. 2024;81(9):905–6.
Objavljeno
2025/02/26
Broj časopisa
Rubrika
Pregledni članak